Author: admin

DelveInsight’s “Pompe Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Pompe Disease, offering comprehensive insights into the Pompe Disease revenue trends, prevalence, and treatment landscape. The report delves into key Pompe Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Pompe Disease therapies. Additionally, we cover the landscape of Pompe Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Pompe Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Pompe Disease space.

To Know in detail about the Pompe Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pompe Disease Market Forecast

Some of the key facts of the Pompe Disease Market Report: 

• The Pompe Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• Among the EU4 and the UK, Germany recorded the highest market size at around USD 94 million, followed by France, having the smallest market size in 2023.

• Asklepios Biopharmaceutical is working on AAV2/8-LSPhGAA, a gene therapy candidate designed to treat Pompe disease by delivering the GAA gene to restore enzyme function. Together with Avalglucosidase alfa from Sanofi, which is a next-generation enzyme replacement therapy, these candidates have the potential to meet the unmet needs in the treatment of Pompe disease.

• Key Pompe Disease Companies: Asklepios Biopharmaceutical, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark Therapeutics, Inc., Asklepios Biopharmaceutical, and others

• Key Pompe Disease Therapies: ACTUS-101, MYOZYME (alglucosidase alfa), GC301, zocaglusagene nuzaparvovec, AT2221, SPK-3006, AAV2/8-LSPhGAA (ACTUS-101), and others

• The Pompe Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pompe Disease pipeline products will significantly revolutionize the Pompe Disease market dynamics.

• According to DelveInsight’s estimates, there were around 13,000 prevalent cases of Pompe disease in the 7MM in 2023, with projections indicating that this number could increase by 2034.

• The EU4 and the UK comprised roughly 25% of all prevalent cases of Pompe disease in 2023.

• In 2023, approximately 8,600 prevalent cases of Pompe disease were reported in the United States, with 98% of these cases occurring in adult patients.

• In 2023, the incidence of the CRIM-positive phenotype in infantile-onset Pompe disease was significantly higher in the United States, at around 80%. This phenotype is marked by the presence of residual enzyme activity, which can affect the progression of the disease and the response to treatment.

Pompe Disease Overview

Pompe disease is a rare, inherited genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This enzyme is essential for breaking down glycogen, a stored form of sugar, into glucose, which is used for energy. When GAA is deficient, glycogen accumulates in the body’s cells, particularly in muscle tissue, leading to progressive muscle weakness and damage.

Get a Free sample for the Pompe Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/pompe-disease-market

Pompe Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pompe Disease Epidemiology Segmentation:

The Pompe Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Pompe Disease

• Prevalent Cases of Pompe Disease by severity

• Gender-specific Prevalence of Pompe Disease

• Diagnosed Cases of Episodic and Chronic Pompe Disease

Download the report to understand which factors are driving Pompe Disease epidemiology trends @ Pompe Disease Epidemiology Forecast

Pompe Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pompe Disease market or expected to get launched during the study period. The analysis covers Pompe Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pompe Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pompe Disease Therapies and Key Companies

• ACTUS-101: Asklepios Biopharmaceutical

• MYOZYME (alglucosidase alfa): Genzyme/ Sanofi

• GC301: GeneCradle Inc

• zocaglusagene nuzaparvovec: Astellas Gene Therapies

• AT2221: Amicus Therapeutics

• SPK-3006: Spark Therapeutics, Inc.

• AAV2/8-LSPhGAA (ACTUS-101): Asklepios Biopharmaceutical

Discover more about therapies set to grab major Pompe Disease market share @ Pompe Disease Treatment Landscape

Pompe Disease Market Drivers

• Increasing Awareness and Diagnosis

• Advancements in Gene Therapy

• Emerging Therapies

• Supportive Regulatory Environment

Pompe Disease Market Barriers

• High Treatment Costs

• Limited Patient Population

• Complexity of Treatment Administration

• Regulatory Challenges

• Variable Disease Progression

Scope of the Pompe Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Pompe Disease Companies: Asklepios Biopharmaceutical, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark Therapeutics, Inc., Asklepios Biopharmaceutical, and others

• Key Pompe Disease Therapies: ACTUS-101, MYOZYME (alglucosidase alfa), GC301, zocaglusagene nuzaparvovec, AT2221, SPK-3006, AAV2/8-LSPhGAA (ACTUS-101), and others

• Pompe Disease Therapeutic Assessment: Pompe Disease current marketed and Pompe Disease emerging therapies

• Pompe Disease Market Dynamics: Pompe Disease market drivers and Pompe Disease market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Pompe Disease Unmet Needs, KOL’s views, Analyst’s views, Pompe Disease Market Access and Reimbursement 

To know more about Pompe Disease companies working in the treatment market, visit @ Pompe Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Pompe Disease Market Report Introduction

2. Executive Summary for Pompe Disease

3. SWOT analysis of Pompe Disease

4. Pompe Disease Patient Share (%) Overview at a Glance

5. Pompe Disease Market Overview at a Glance

6. Pompe Disease Disease Background and Overview

7. Pompe Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Pompe Disease 

9. Pompe Disease Current Treatment and Medical Practices

10. Pompe Disease Unmet Needs

11. Pompe Disease Emerging Therapies

12. Pompe Disease Market Outlook

13. Country-Wise Pompe Disease Market Analysis (2020–2034)

14. Pompe Disease Market Access and Reimbursement of Therapies

15. Pompe Disease Market Drivers

16. Pompe Disease Market Barriers

17.  Pompe Disease Appendix

18. Pompe Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pompe Disease Market on Track for Major Expansion by 2034, According to DelveInsight | Asklepios Biopharma, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark

The Diabetic Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Nephropathy pipeline products will significantly revolutionize the Diabetic Nephropathy market dynamics.  

DelveInsight’s “Diabetic Nephropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Nephropathy, historical and forecasted epidemiology as well as the Diabetic Nephropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diabetic Nephropathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Diabetic Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Nephropathy Market Insights

Some of the key facts of the Diabetic Nephropathy Market Report: 

• The Diabetic Nephropathy market size was valued ~USD 2,800 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• Throughout the forecast period (2024–2034), pipeline candidates like VM202 (donaperminogene seltoplasmid), VX-548, LX9211, and others are anticipated to contribute to the growth of the diabetic neuropathy market size.

• Emerging therapies, including LX9211, VX-548, Engenesis/VM202 (donaperminogene seltoplasmid), and sublingual Cannabidiol (CBD), are anticipated to launch in various regions within the 7MM countries during the forecast period.

• In the 7MM, the United States held the largest market size, capturing approximately 80% of the diabetic neuropathy market share compared to the EU4, the UK, and Japan in 2023.

• According to the American Diabetes Association, chronic diabetic sensory polyneuropathy (DSPN) is the most prevalent type of diabetic neuropathy, representing approximately 75% of all cases.

• In the 7MM, the United States represented the largest share of diabetic neuropathy cases, comprising approximately 60% of the diagnosed prevalent cases in 2023.

• Among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of diabetic neuropathy, while Spain had the lowest.

• In 2023, the highest number of type-specific cases of diabetic neuropathy in the 7MM were recorded for peripheral diabetic neuropathy, and this number is expected to rise by 2034.

• Key Diabetic Nephropathy Companies: AstraZeneca, NeuroBo Pharmaceuticals, Don-A ST, MThera Pharma , Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharmaceuticals, Helixmith, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, and others

• Key Diabetic Nephropathy Therapies: MEDI7352, NB-01, DA-9801, QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), VM202, LX9211, GRC 17536, Ricolinostat, CBD, and others

• The Diabetic Nephropathy epidemiology based on gender analyzed that the prevalence of Diabetic Nephropathy increases significantly with age

Diabetic Nephropathy Overview

Diabetic nephropathy is a serious kidney-related complication of diabetes, characterized by damage to the blood vessels in the kidneys due to prolonged high blood sugar levels. This condition leads to a gradual decline in kidney function and can result in end-stage renal disease (ESRD) if not managed properly. Early signs of diabetic nephropathy include the presence of protein in the urine (albuminuria) and elevated blood pressure. Risk factors for developing this condition include poor glycemic control, hypertension, and a family history of kidney disease. Management focuses on controlling blood sugar and blood pressure levels, as well as lifestyle changes and medications to slow the progression of kidney damage.

Get a Free sample for the Diabetic Nephropathy Market Report: 

https://www.delveinsight.com/report-store/diabetic-neuropathy-market

Diabetic Nephropathy Market  

The dynamics of the Diabetic Nephropathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

Diabetic Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Nephropathy Epidemiology Segmentation:

The Diabetic Nephropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Prevalent Cases of Diabetic Nephropathy in the 7MM

• Prevalent Cases of Painful Diabetic Nephropathy in the 7MM

• Treated Cases of Diabetic Nephropathy in the 7MM

Download the report to understand which factors are driving Diabetic Nephropathy epidemiology trends @ Diabetic Nephropathy Epidemiological Insights

Diabetic Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Nephropathy market or expected to get launched during the study period. The analysis covers Diabetic Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Nephropathy Therapies and Key Companies

• MEDI7352: AstraZeneca

• NB-01/ DA-9801: NeuroBo Pharmaceuticals/ Don-A ST/ MThera Pharma

• QUTENZA (capsaicin): Grünenthal/Averitas Pharma

• TARLIGE (mirogabalin besylate): Daiichi Sankyo

• Engensis (VM202): Helixmith

• Suzetrigine (VX-548): Vertex Pharmaceuticals

• VM202: Helixmith

• LX9211: Lexicon Pharmaceuticals

• GRC 17536: Glenmark Pharmaceuticals

• Ricolinostat: Regenacy Pharmaceuticals

• CBD: Pure Green

To know more about Diabetic Nephropathy treatment, visit @ Diabetic Nephropathy Medications

Diabetic Nephropathy Market Drivers

• Diabetic Nephropathy is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition.

• Treatment of Diabetic Nephropathy has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of Diabetic Nephropathy patients.

• Challenges in diagnosis

• Development of novel therapies

• Limitations in gene therapy

• Poor disease understanding

• Clinical biomarkers 

Scope of the Diabetic Nephropathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Diabetic Nephropathy Companies: AstraZeneca, NeuroBo Pharmaceuticals, Don-A ST, MThera Pharma, Grünenthal, Averitas Pharma, Daiichi Sankyo, Helixmith, Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, Pure Green, and others

• Key Diabetic Nephropathy Therapies: MEDI7352, NB-01, DA-9801, QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), VM202, LX9211, GRC 17536, Ricolinostat, CBD, and others

• Diabetic Nephropathy Therapeutic Assessment: Diabetic Nephropathy current marketed and Diabetic Nephropathy emerging therapies

• Diabetic Nephropathy Market Dynamics: Diabetic Nephropathy market drivers and Diabetic Nephropathy market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Diabetic Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Diabetic Nephropathy Market Access and Reimbursement 

Discover more about therapies set to grab major Diabetic Nephropathy market share @ Diabetic Nephropathy Treatment Landscape

Table of Contents 

1. Diabetic Nephropathy Market Report Introduction

2. Executive Summary for Diabetic Nephropathy

3. SWOT analysis of Diabetic Nephropathy

4. Diabetic Nephropathy Patient Share (%) Overview at a Glance

5. Diabetic Nephropathy Market Overview at a Glance

6. Diabetic Nephropathy Disease Background and Overview

7. Diabetic Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Nephropathy 

9. Diabetic Nephropathy Current Treatment and Medical Practices

10. Diabetic Nephropathy Unmet Needs

11. Diabetic Nephropathy Emerging Therapies

12. Diabetic Nephropathy Market Outlook

13. Country-Wise Diabetic Nephropathy Market Analysis (2020–2034)

14. Diabetic Nephropathy Market Access and Reimbursement of Therapies

15. Diabetic Nephropathy Market Drivers

16. Diabetic Nephropathy Market Barriers

17.  Diabetic Nephropathy Appendix

18. Diabetic Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | AstraZeneca, NeuroBo Pharma, Don-A ST, MThera Pharma , Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex

“PD-1 Non-Small Cell Lung Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 Non-Small Cell Lung Cancer Market.

The PD-1 Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report: 

• Companies across the globe are diligently working toward developing novel PD-1 Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 

• PD-1 Non-Small Cell Lung Cancer companies working in the treatment market are Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others, are developing therapies for the PD-1 Non-Small Cell Lung Cancer treatment 

• Emerging PD-1 Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others are expected to have a significant impact on the PD-1 Non-Small Cell Lung Cancer market in the coming years.   

• In January 2024, Gilead Sciences reported that the Phase 3 EVOKE-01 trial failed to achieve its primary endpoint of overall survival (OS) in patients with previously treated metastatic non-small cell lung cancer (NSCLC). The EVOKE-01 study is comparing Trodelvy (sacituzumab govitecan-hziy; SG) with docetaxel in individuals with metastatic or advanced NSCLC who have experienced disease progression following platinum-based chemotherapy and checkpoint inhibitor therapy.

• In February 2024, The FDA awarded breakthrough therapy designation to BAY 2927088, a new oral small molecule tyrosine kinase inhibitor (TKI), for the treatment of patients with unresectable or metastatic HER2-mutated non-small cell lung cancer (NSCLC).

• In June 2023, BioNTech SE has reported that the first patient with non-small cell lung cancer (NSCLC) has been treated in a crucial Phase 3 trial assessing the company’s next-generation anti-CTLA-4 antibody candidate, BNT316/ONC-392 (gotistobart). This trial aligns with BioNTech’s plan to launch several pivotal trials in 2023 and 2024.

• In June 2023, At the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023), Qilu Pharmaceutical showcased ongoing trial progress through a poster presentation on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody designed for immunotherapy. This presentation highlighted its utilization in two Phase III clinical studies focused on non-small cell lung carcinoma (NSCLC).

PD-1 Non-Small Cell Lung Cancer Overview

PD-1 Non-Small Cell Lung Cancer (NSCLC) refers to a subtype of lung cancer characterized by the expression of the programmed cell death protein 1 (PD-1) pathway, which plays a crucial role in regulating the immune system. In NSCLC, cancer cells can exploit this pathway to evade immune detection, allowing tumors to grow and spread.

Get a Free Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment

https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight

Emerging PD-1 Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• GB226: Genor Biopharma

• BA-1104: Shandong Boan Biotechnology

• PF-06801591: Pfizer

• AZD2936: AstraZeneca

• HX008: Lepu Biopharma

• Dostarlimab: GlaxoSmithKline

• INCMGA00012: Incyte Corporation

• AK-112: Akeso Biopharma

• Zimberelimab: Arcus Biosciences

• Ivonescimab: Summit Therapeutics

• Sasanlimab: Pfizer

• Rilvegostomig: AstraZeneca

• SGN-PDL1V: Seagen

PD-1 Non-Small Cell Lung Cancer Route of Administration

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

PD-1 Non-Small Cell Lung Cancer Molecule Type

PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

• PD-1 Non-Small Cell Lung Cancer Assessment by Product Type

• PD-1 Non-Small Cell Lung Cancer By Stage and Product Type

• PD-1 Non-Small Cell Lung Cancer Assessment by Route of Administration

• PD-1 Non-Small Cell Lung Cancer By Stage and Route of Administration

• PD-1 Non-Small Cell Lung Cancer Assessment by Molecule Type

• PD-1 Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s PD-1 Non-Small Cell Lung Cancer Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further PD-1 Non-Small Cell Lung Cancer product details are provided in the report. Download the PD-1 Non-Small Cell Lung Cancer pipeline report to learn more about the emerging PD-1 Non-Small Cell Lung Cancer therapies

Some of the key companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for PD-1 Non-Small Cell Lung Cancer are – Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Symphogen, and others.

PD-1 Non-Small Cell Lung Cancer Pipeline Analysis:

The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.

• PD-1 Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer drugs and therapies

PD-1 Non-Small Cell Lung Cancer Pipeline Market Drivers

• Increase in Patient Burden, development of Efficient Novel Treatments, increasing healthcare expenditures are some of the important factors that are fueling the PD-1 Non-Small Cell Lung Cancer Market.

PD-1 Non-Small Cell Lung Cancer Pipeline Market Barriers

• However, uncertainty about the clinical response to PD-1/PD-L1 blockade therapy in NSCLC, NSCLC with driver mutations represent a challenging population and other factors are creating obstacles in the PD-1 Non-Small Cell Lung Cancer Market growth.

Scope of PD-1 Non-Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global

• Key PD-1 Non-Small Cell Lung Cancer Companies: Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others

• Key PD-1 Non-Small Cell Lung Cancer Therapies: GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others

• PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies

• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers 

Request for Sample PDF Report for PD-1 Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials

Table of Contents

1. PD-1 Non-Small Cell Lung Cancer Report Introduction

2. PD-1 Non-Small Cell Lung Cancer Executive Summary

3. PD-1 Non-Small Cell Lung Cancer Overview

4. PD-1 Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics

6. PD-1 Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. PD-1 Non-Small Cell Lung Cancer Mid Stage Products (Phase II)

8. PD-1 Non-Small Cell Lung Cancer Early Stage Products (Phase I)

9. PD-1 Non-Small Cell Lung Cancer Preclinical Stage Products

10. PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment

11. PD-1 Non-Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. PD-1 Non-Small Cell Lung Cancer Key Companies

14. PD-1 Non-Small Cell Lung Cancer Key Products

15. PD-1 Non-Small Cell Lung Cancer Unmet Needs

16 . PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers

17. PD-1 Non-Small Cell Lung Cancer Future Perspectives and Conclusion

18. PD-1 Non-Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PD-1 Non-Small Cell Lung Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Summit Therapeutics, Arcus Biosciences,GSK, Pfizer

“Primary Hyperoxyaluria Clinical Trials”

(Albany, United States) “Primary Hyperoxaluria Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report:

• Primary Hyperoxaluria Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years. 
• Primary Hyperoxaluria companies working in the treatment market are Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Biocodex, and others, are developing therapies for the Primary Hyperoxaluria treatment 

• Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- Lumasiran, nedosiran, Stiripentol, DCR-PHXC, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.   
• In October 2023, Novo Nordisk has obtained approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) injection, aimed at lowering urinary oxalate levels in children aged nine and above, and adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function. PH1 is a rare genetic disorder that leads to oxalate overproduction by the liver, affecting approximately one in 38,600 individuals worldwide. The approved doses of Rivfloza are 80mg, 128mg, or 160mg, administered monthly as a subcutaneous ribonucleic acid interference therapy. This approval is based on data from the pivotal Phase II PHYOX2 clinical study and interim results from the ongoing Phase III PHYOX3 extension study.
• In October 2023, The Food and Drug Administration (FDA) has approved Rivfloza™ (nedosiran) to reduce urinary oxalate levels in children aged nine and older, as well as adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function (e.g., estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m²).

Primary Hyperoxaluria Overview

Primary hyperoxaluria is a rare genetic disorder characterized by excessive production of oxalate, a compound that can form kidney stones and lead to kidney damage. It results from mutations in one of three genes: AGXT, GRHPR, or HOGA1, corresponding to different types of the condition.

The excess oxalate can precipitate in the kidneys, leading to calcium oxalate stone formation, which can cause severe pain, hematuria, and potentially chronic kidney disease. Symptoms often begin in childhood or early adulthood, though they can vary widely in onset and severity.

Diagnosis typically involves urine tests that show high levels of oxalate, along with genetic testing to confirm the specific mutation. Treatment options are limited and may include dietary modifications to reduce oxalate intake, increased fluid intake to dilute urine, and medications such as pyridoxine (vitamin B6) for certain types. In severe cases, interventions like dialysis or kidney transplantation may be necessary.

Early detection and management are crucial to prevent complications and preserve kidney function. Ongoing research aims to improve understanding of the disease and develop more effective treatments.

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

• Lumasiran: Alnylam Pharmaceuticals
• nedosiran: Dicerna Pharmaceuticals
• Stiripentol: Biocodex
• DCR-PHXC: Dicerna Pharmaceuticals

Primary Hyperoxaluria Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Primary Hyperoxaluria Molecule Type

Primary Hyperoxaluria Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Primary Hyperoxaluria Pipeline Therapeutics Assessment

• Primary Hyperoxaluria Assessment by Product Type
• Primary Hyperoxaluria By Stage and Product Type
• Primary Hyperoxaluria Assessment by Route of Administration
• Primary Hyperoxaluria By Stage and Route of Administration
• Primary Hyperoxaluria Assessment by Molecule Type
• Primary Hyperoxaluria by Stage and Molecule Type

DelveInsight’s Primary Hyperoxaluria Report covers around 6+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxaluria are – Dicerna Pharmaceuticals, Allena Pharmaceuticals, Genentech, Biocode, Alnylum Pharm, OxThera, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, and others.

Primary Hyperoxaluria Pipeline Analysis:

The Primary Hyperoxaluria pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
• Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Hyperoxaluria drugs and therapies

Primary Hyperoxaluria Pipeline Market Drivers

• Genetic Advancements, Innovative Treatments, Increased Diagnosis Rates, Orphan Drug Designation, Rising Awareness, are some of the important factors that are fueling the Primary Hyperoxaluria Market.

Primary Hyperoxaluria Pipeline Market Barriers

• However, High Development Costs, Regulatory Challenges, Limited Patient Population, Clinical Trial Difficulties, Uncertain Long-term Efficacy, and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

Scope of Primary Hyperoxaluria Pipeline Drug Insight    

• Coverage: Global
• Key Primary Hyperoxaluria Companies: Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Biocodex, and others
• Key Primary Hyperoxaluria Therapies: Lumasiran, nedosiran, Stiripentol, DCR-PHXC, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers 

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials

Table of Contents

1. Primary Hyperoxaluria Report Introduction

2. Primary Hyperoxaluria Executive Summary

3. Primary Hyperoxaluria Overview

4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxaluria Pipeline Therapeutics

6. Primary Hyperoxaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxaluria Mid Stage Products (Phase II)

8. Primary Hyperoxaluria Early Stage Products (Phase I)

9. Primary Hyperoxaluria Preclinical Stage Products

10. Primary Hyperoxaluria Therapeutics Assessment

11. Primary Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxaluria Key Companies

14. Primary Hyperoxaluria Key Products

15. Primary Hyperoxaluria Unmet Needs

16 . Primary Hyperoxaluria Market Drivers and Barriers

17. Primary Hyperoxaluria Future Perspectives and Conclusion

18. Primary Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Hyperoxyaluria Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight | Dicerna Pharma, Allena Pharma, Genentech, Biocode, Alnylum

“Benign Prostatic Hyperplasia Clinical Trials”

(Albany, United States) As per DelveInsight’s assessment, globally, Benign Prostatic Hyperplasia pipeline constitutes 7+ key companies continuously working towards developing 8+ Benign Prostatic Hyperplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Benign Prostatic Hyperplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Benign Prostatic Hyperplasia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Benign Prostatic Hyperplasia Market.

Some of the key takeaways from the Benign Prostatic Hyperplasia Pipeline Report:

• Benign Prostatic Hyperplasia Companies across the globe are diligently working toward developing novel Benign Prostatic Hyperplasia treatment therapies with a considerable amount of success over the years. 
• Benign Prostatic Hyperplasia companies working in the treatment market are AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others, are developing therapies for the Benign Prostatic Hyperplasia treatment.
• Emerging Benign Prostatic Hyperplasia therapies in the different phases of clinical trials are- AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others are expected to have a significant impact on the Benign Prostatic Hyperplasia market in the coming years.  
• In October 2023, Nymox Pharmaceutical Corporation has disclosed that their recent application for Fexapotide Triflutate, intended for addressing symptoms associated with benign prostate enlargement (commonly known as benign prostatic hyperplasia or BPH), has been officially recognized by the UK authorities, specifically the UK Medicines & Healthcare products Regulatory Agency (MHRA). The formal evaluation process is now underway. The product will be marketed under the trademarked name NYMOZARFEX. The Marketing Authorization Application (MAA) was lodged on September 25, 2023.

Benign Prostatic Hyperplasia Overview

Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a common condition that affects older men. The prostate gland, which is part of the male reproductive system, surrounds the urethra (the tube that carries urine from the bladder out of the body).

Get a Free Sample PDF Report to know more about Benign Prostatic Hyperplasia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-pipeline-insight

Emerging Benign Prostatic Hyperplasia Drugs Under Different Phases of Clinical Development Include:

• AIV007: AiViva BioPharma
• CKD-846: Chong Kun Dang
• DTT106: EMS
• Paclitaxel: Urotronic Inc.
• RT-310: Resurge Therapeutics Inc
• Teverelix trifluoroacetate: Antev
• Fexapotide: Nymox Pharmaceutical
• GI198745: GlaxoSmithKline
• DKF-313: Dongkook Pharmaceutical
• Silodosin: RECORDATI GROUP
• ASP4901: Astellas Pharma Inc
• Tadalafil: Eli Lilly and Company
• PRX302: Sophiris Bio Corp
• Levitra (Vardenafil, BAY38-9456): Bayer
• PRX302: Sophiris Bio Corp
• WC3055: Warner Chilcott
• NX-1207: Nymox Corporation
• QLT0074: QLT Inc.
• Tamsulosin Hydrochloride: NeoTract, Inc.
• Ningmitai capsule: Xintian Pharmaceutical

Benign Prostatic Hyperplasia Route of Administration

Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Benign Prostatic Hyperplasia Molecule Type

Benign Prostatic Hyperplasia Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Benign Prostatic Hyperplasia Pipeline Therapeutics Assessment

• Benign Prostatic Hyperplasia Assessment by Product Type
• Benign Prostatic Hyperplasia By Stage and Product Type
• Benign Prostatic Hyperplasia Assessment by Route of Administration
• Benign Prostatic Hyperplasia By Stage and Route of Administration
• Benign Prostatic Hyperplasia Assessment by Molecule Type
• Benign Prostatic Hyperplasia by Stage and Molecule Type

DelveInsight’s Benign Prostatic Hyperplasia Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Benign Prostatic Hyperplasia product details are provided in the report. Download the Benign Prostatic Hyperplasia pipeline report to learn more about the emerging Benign Prostatic Hyperplasia therapies

Some of the key companies in the Benign Prostatic Hyperplasia Therapeutics Market include:

Key companies developing therapies for Benign Prostatic Hyperplasia are – Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC, Astellas Pharma Inc., and others.

Benign Prostatic Hyperplasia Pipeline Analysis:

The Benign Prostatic Hyperplasia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Benign Prostatic Hyperplasia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Benign Prostatic Hyperplasia Treatment.
• Benign Prostatic Hyperplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Benign Prostatic Hyperplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Benign Prostatic Hyperplasia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Benign Prostatic Hyperplasia drugs and therapies

Benign Prostatic Hyperplasia Pipeline Market Drivers

• The prevalence of this disease drives demand for treatments, creating a growth opportunity for pharmaceutical companies and medical device manufacturers in the BPH market thus fuels research, development, and innovation, leading to the introduction of new therapies and technologies.

Benign Prostatic Hyperplasia Pipeline Market Barriers

• The presence of significant side effects linked to BPH treatments can deter patient adherence and acceptance, limiting market expansion as concerns about safety and tolerability affect physician prescribing patterns and hinder uptake of therapies

Scope of Benign Prostatic Hyperplasia Pipeline Drug Insight    

• Coverage: Global
• Key Benign Prostatic Hyperplasia Companies: AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others
• Key Benign Prostatic Hyperplasia Therapies: AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others
• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers 

Request for Sample PDF Report for Benign Prostatic Hyperplasia Pipeline Assessment and clinical trials

Table of Contents

1. Benign Prostatic Hyperplasia Report Introduction

2. Benign Prostatic Hyperplasia Executive Summary

3. Benign Prostatic Hyperplasia Overview

4. Benign Prostatic Hyperplasia- Analytical Perspective In-depth Commercial Assessment

5. Benign Prostatic Hyperplasia Pipeline Therapeutics

6. Benign Prostatic Hyperplasia Late Stage Products (Phase II/III)

7. Benign Prostatic Hyperplasia Mid Stage Products (Phase II)

8. Benign Prostatic Hyperplasia Early Stage Products (Phase I)

9. Benign Prostatic Hyperplasia Preclinical Stage Products

10. Benign Prostatic Hyperplasia Therapeutics Assessment

11. Benign Prostatic Hyperplasia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Benign Prostatic Hyperplasia Key Companies

14. Benign Prostatic Hyperplasia Key Products

15. Benign Prostatic Hyperplasia Unmet Needs

16 . Benign Prostatic Hyperplasia Market Drivers and Barriers

17. Benign Prostatic Hyperplasia Future Perspectives and Conclusion

18. Benign Prostatic Hyperplasia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Benign Prostatic Hyperplasia Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight | Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC

“Hyperuricemia Treatment Market”

(Albany, US) DelveInsight’s “Hyperuricemia – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for sample report @ Hyperuricemia Treatment Market

Some facts of the Hyperuricemia Market Report are:

• According to DelveInsight, Hyperuricemia market is expected to grow at a decent CAGR during the forecast period.
• Hyperuricemia companies working in the treatment market are LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others, are developing therapies for the Hyperuricemia treatment.
• Emerging Hyperuricemia therapies in the different phases of clinical trials are – Tigulixostat(LC350189), SAP-001, D-0120, SHR4640, FYU-981, TULY, Rasburicase, KUX-1151, Febuxostat, RDEA594, RDEA806, dontinurad, Tranilast, Arhalofenate, URC102, SEL-212, and others are expected to have a significant impact on the Hyperuricemia market in the coming years.   
• The most recent significant study of hyperuricemia and gout found that 43.3 million Americans have the condition.
• The prevalence rate of hyperuricemia in the general population is estimated at 20-25%, but only 4-6% in premenopausal women
• The prevalence of gout is 5.9% in men and 2% in women.
• In June 2022, Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc., a commercial biopharmaceutical company focused on developing and manufacturing, and distributing non-opioid therapies for patients suffering from acute and chronic pain, entered into a license and commercialization agreement with RxOmeg Therapeutics LLC for the exclusive right to market and distribute in the U.S. Gloperba is an oral gout medication for adults.
• In November 2021, Allena Pharmaceuticals, Inc., which is a late-stage biopharmaceutical company using its novel oral biologic platform to discover, develop, and commercialize first-in-class oral Enzyme therapeutics for difficult-to-treat metabolic diseases, announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received FDA Fast Track designation. ALLN-346 is now in Phase 2 testing for the treatment of hyperuricemia in gout patients with severe CKD.

Request for sample report to know more about Hyperuricemia epidemiology trends @ Hyperuricemia Prevalence

Scope of the Hyperuricemia Market Report

• The Hyperuricemia market report covers the descriptive overview of Hyperuricemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Hyperuricemia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Hyperuricemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Hyperuricemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hyperuricemia market

Request for sample report @ Hyperuricemia Market Forecast

Hyperuricemia Overview:

Hyperuricemia occurs when there’s too much uric acid in your blood. High uric acid levels can lead to several diseases, including a painful type of arthritis called gout. Elevated uric acid levels are also associated with health conditions such as heart disease, diabetes, and kidney disease.

Uric acid is formed when purines break down in your body. Purines are chemicals found in certain foods. This typically includes:

• red meat
• organ meat
• seafood
• beans

Normally, your body rids itself of uric acid when you urinate. Hyperuricemia occurs when your body either makes too much uric acid or is unable to excrete enough of it. It usually happens because your kidneys aren’t eliminating it quickly enough.

Excess uric acid levels in your blood can lead to the formation of crystals. Although these can form anywhere in the body, they tend to form in and around your joints and in your kidneys. Your body’s defensive white blood cells may attack the crystals, causing inflammation and pain.

Rates of hyperuricemia have risen sharply since 1960.

Hyperuricemia Treatment Market

Therapeutic strategies used to treat hyperuricemia are often focused on limiting acute episodes characterized by an inflammatory response of cells triggered by urate crystal deposition. These events are counteracted using NSAIDs, colchicine, or glucocorticoids which act through different mechanisms. NSAIDs‘ effect is due to the inhibition of prostaglandin generation by up-regulated COX-2, recognized as the most important event in the stimulation of inflammatory responses which characterize gouty arthritis attacks. Further, in vitro studies have shown that high concentrations of colchicine suppress inflammation by blocking IL-1 beta processing in monocytes stimulated by monosodium urate (MSU).

Moreover, it downregulates tyrosine kinases and phospholipases in neutrophils, inhibiting chemotaxis, superoxide anion production, adhesion to cellular substrata, and mobilization and release of lysosomal enzymes during phagocytosis. Currently, the drugs of first choice for long-term management of hyperuricemia are XO inhibitors with uricostatic features (eg, allopurinol, oxypurinol, febuxostat), which lower serum uric acid (SUA) levels through competitive inhibition of XO. Following oral administration, allopurinol is rapidly absorbed in the upper gastrointestinal tract, reaching peak plasma concentrations in approximately 30 minutes, and it has a plasma half-life of 2–3 hours. The main active metabolite of allopurinol is oxypurinol, excreted and partly reabsorbed in the kidneys; it has the same mechanism of action, a longer plasma half-life of 14–30 hours, but lower oral bioavailability than its precursor.

Febuxostat is a new non purine, selective inhibitor of XO, that blocks the active pterin–molybdenum center of the enzyme complex, and unlike allo/oxypurinol, does not determine enzyme turnover, avoiding the consequent undesired production of ROS. Following oral administration, it is completely absorbed in the upper gastrointestinal tract, reaching peak plasma concentrations in approximately 1 hour, with a plasma half-life of 1.5–16 hours It is metabolized and excreted predominantly through hepatic conjugation processes. The standard dosage of febuxostat is 80–120 mg/day, even though remarkable decreases in SUA levels have been observed with a lower dose of 40 mg/day. Takeda’s ULORIC (febuxostat), is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Click here to know in detail about the Hyperuricemia Market Drivers, Barriers and Trends @ Hyperuricemia Market Dynamics

The major players covered in the hyperuricemia drugs market are:

• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Sun Pharmaceutical Industries Limited
• Hikma Pharmaceutical PLC
• Dr. Reddy’s Laboratories Ltd
• Sanofi
• Sandoz AG
• Amneal Pharmaceuticals LLC
• And Many Others

Request for sample report @ Hyperuricemia Clinical Trials

Table of Contents:

1. Key Insights

2. Executive Summary of Hyperuricemia

3. Competitive Intelligence Analysis for Hyperuricemia

4. Hyperuricemia: Market Overview at a Glance

5. Hyperuricemia: Disease Background and Overview

6. Patient Journey

7. Hyperuricemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hyperuricemia Treatment

11. Marketed Products

12. Emerging Therapies

13. Hyperuricemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hyperuricemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hyperuricemia Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight